Enlivex Therapeutics Ltd. (ENLV )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ENLV
- Company Enlivex Therapeutics Ltd.
- Price $1.16
- Changes Percentage 11.06
- Change 0.12
- Day Low $1.03
- Day High $1.24
- Year High $2.1
- Year Low $0.66
- Market Cap $28,070,046
- Price Avg 50 EMA (D) $0.96
- Price Avg 200 EMA (D) $1.07
- Exchange NASDAQ
- Volume 797,713
- Average Volume 4,177,880
- Open $1.03
- Previous Close $1.04
- EPS -0.54
- PE -2.14
- Earnings Announcement 2026-02-25 12:00:00
- Shares Outstanding $24,303,070
Company brief: ENLIVEX THERAPEUTICS LTD. (ENLV )
- Healthcare
- Biotechnology
- Dr. Oren Hershkovitz Ph.D.
- https://www.enlivex.com
- IL
- N/A
- 07-31-2014
- IL0011319527
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.